Michael A. Kass, M.D., of Washington University School of Medicine, St. Louis, and colleagues in the Ocular Hypertension Treatment Study Group compared the safety and efficacy of earlier vs. later ...

The Ocular Hypertension Treatment Study (OHTS) is a multicentered, randomized, controlled clinical trial with the primary goal to determine the safety and efficacy of topical ocular hypotensive ...

Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20 ...

Ophthalmology > Ophthalmology Implant for Ocular Hypertension, Glaucoma Gets FDA Green Light — A single travoprost implant proved noninferior to timolol eye drops, with good safety by Charles ...

The FDA approved iDose TR for the treatment of open-angle glaucoma and ocular hypertension. Commercial launch activities for the implant are anticipated to begin in the first quarter of 2024.

The ocular hypertension treatment market is highly competitive, with major players including Bausch + Lomb, Alcon, Santen Pharmaceutical, AbbVie, Nicox, Kowa, Qlaris Bio, Noveome Biotherapeutics ...

The Ocular Hypertension Treatment Study showed that higher IOP is a significant risk factor for progression to primary open-angle glaucoma (POAG), and that IOP-lowering medications are protective ...

Alcon (ALC) announced he full U.S. commercial availability of Voyager DSLT, the first and only Direct Selective Laser Trabeculoplasty device . Voyager DSLT is uniquely poised to accelerate the ...

References Santen and UBE received FDA approval for Omlonti ® (omidenepag isopropyl ophthalmic solution) 0.002% for the reduction of elevated intraocular pressure in patients with primary open ...

JAMA Ophthalmology Source Reference: Singh RK, et al "Polygenic risk scores for glaucoma onset in the Ocular Hypertension Treatment Study" JAMA Ophthalmol 2024; DOI: 10.1001/jamaophthalmol.2024.0151.

Ocular Therapeutix’s earlier stage development assets include OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases.